|
|||||
|
|
Development of CDK2 and CDK5 Dual Degrader TMX-2172 |
|
| Authors: | Dr Mingxing Teng Dr Jie Jiang Zhixiang He Dr Nicholas P Kwiatkowski Dr Katherine A Donovan Dr Caitlin E Mills Chiara Victor Dr John M Hatcher Dr Eric S Fischer Dr Peter K Sorger Dr Tinghu Zhang Dr Nathanael S Gray |
| Institution: | 1. Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;2. Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA These authors contributed equally to this work.;3. Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA;4. Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA |
| Abstract: | |
| Keywords: | cancer CDK2 CDK5 cell cycle drug design protein degradation |